Анджела Маас - Женское сердце. Современный подход к здоровью женщин

Panoulas V. F., Francis D. P., Ruparelia N. et al. Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomized controlled trials including 3758 patients // Int J Cardiol, 2018. — № 250. — P. 66–72.

Dziadzko V., Clavel M. A., Dziadzko M. et al. Outcome and undertreatment of mitral regurgitation: a community cohort study // Lancet, 2018. — № 391. — P. 960–969.

Van Loenen Martinet F. A., van der Bom T., Bouma B. J. Mitralis-klepinsufficiëntie. Wel of niet onderbehandeld? // Ned Tijdschr Geneeskd, 2018. — № 162. — D3028. (Mitral valve insufficiency. Has it been undertreated?)

Shapiro C. L. Cancer survivorship // N Engl J Med, 2018. — № 379. — P. 2438–2450.

Maas A. H., Ottevanger N., Atsma F. et al. Cardiovascular surveillance in breast cancer treatment: A more individualized approach is needed // Maturitas, 2016. — № 89. — P. 58–62.

Mehta L. S., Watson K. E., Barac A. et al. Cardiovascular disease and breast cancer: where these entities intersect. A scientific statement of the American Heart Association // Circulation, 2018. — № 137 (8). — e30–e66.

Zamorano J. L., Lancellotti P., Rodriguez Muñoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) // Eur Heart J, 2016. — № 37 (36). — P. 2768–2801.

Darby S. C., Ewertz M., McGale P. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer // N Engl J Med, 2013. — № 368 (11). — P. 987–998.

Boekel N. B., Jacobse J. N., Schaapveld M. et al. Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer // Br J Cancer, 2018. — № 119 (4). — P. 408–418.

Nadruz W., West E., Sengelø M. et al. Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy // Heart, 2019. — № 105. — P. 34–41.

Chen J., Long J. B., Hurria A. et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer // J Am Coll Cardiol, 2012. — № 60. — P. 2504–2512.

Boerman L. M., Maas SWMC, van der Meer P. et al. Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: a cross-sectional study // Eur J Cancer, 2017. — № 81. — P. 56–65.

Dobbin S. J. H., Cameron A. C., Petrie M. C. et al. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors // Heart, 2018. — № 104 (24). — P. 1995–2002.

Cardinale D., Colombo A., Bacchiani G. et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy // Circulation, 2015. — № 131. — P. 1981–1988.

Gulati G., Heck S. L., Ree A. H. et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol // Eur Heart J, 2016. — № 37 (21). — P. 1671–1680.

Arts-de Jong M., Maas A. H. E. M., Massuger L. F. et al. BRCA1/2 mutation carriers are potentially at higher cardiovascular risk // Crit Rev Oncol Hematol, 2014. — № 91 (2). — P. 159–171.

Latchamsetty R., Bogun F. Premature Ventricular Complexes and Premature Ventricular Complex Induced Cardiomyopathy // Curr Probl Cardiol, 2015. — № 40. — P. 379–422.

Rivero A., Curtis A. B. Sex differences in arrhythmias // Curr Opin Cardiol, 2010. — № 25 (1). — P. 8–15.

Yarnoz M. J., Curtis A. B. More reasons why men and women are not the same (gender differences in electrophysiology and arrhythmias) // Am J Cardiol, 2008. — № 101 (9). — P. 1291–1296.

Saner H., Van der Velde E. eHealth in cardiovascular medicine: a clinical update // Eur J Preventive Cardiol, 2016. — № 23 (2S). — P. 5–12.

Treskes R. W., Wildbergh T. X., Schalij M. J., Scherptong R. W. C. Expectations and perceived barriers to widespread implementation of e-health in cardiology practice: results from a national survey in the Netherlands // Neth Heart J, 2019. — № 27. — P. 18–23.

Piccini J. P., Simon D. N., Steinberg B. A. et al. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF registry // JAMA Cardiol, 2016. — № 1 (3). — P. 282–291.

Linde C., Bongiorni M. G., Birgersdotter-Green U. et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society // Europace, 2018. — № 20 (10). — P. 1565–1565ao.

Rolden H. J. A., Maas A. H. E. M., van der Wilt G. J., Grutters J. P. C. ‘Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation; empirical evidence needed’ // BMC Cardiovasc Disord, 2017. — № 17 (1). — P. 260.

Benito B., Sarkozy A., Mont L. Gender differences in clinical manifestation of Brugada Syndrome // J Am Coll Cardiol, 2008. — № 52 (19). — P. 1567–1573.

MacFadden D. R., Tu J. V., Chong A. et al. Evaluating sex differences in population-based utilization of implantable cardioverter-defibrillators: role of cardiac conditions and non cardiac comorbidities // Heart Rhythm, 2009. — № 6 (9). — P. 1289–1296.

Priori S. G., Schwartz P. J., Napolitano C. et al. Risk stratification in the long QT-syndrome // N Engl J Med, 2003. — № 348 (19). — P. 1866–1874.

Речь идет о рассказе Исаака Башевиса-Зингера «Йентл, мальчик из иешивы», в котором главная героиня Йентл притворяется мальчиком, чтобы учиться в высшем духовном заведении (иешиве). Прим. ред.